Abstract: The present invention provides a method of treating a disease or conditions associated with a dysfunction of TREM2 in a human patient, such as Alzheimer's disease, comprising administering to the patient a TREM2 agonist. In another aspect, the invention provides a method of assaying a biological sample taken from a patient having Alzheimer's for biomarkers to determine potential benefit or if the disease has an increased probability of responding to treatment with a TREM2 agonist.

Abstract: A plant comprising a genome having an introgression which comprises a polynucleotide sequence encoding a polypeptide having a terpene synthase activity or a transporter activity, the introgression comprising allelic variation(s) as compared to a genome of a recurrent parent of the plant, is disclosed. Organisms comprising a genome having been genetically modified to express a polypeptide having a terpene synthase activity or a transporter activity are also disclosed. Methods of modulating terpene synthesis or transport of metabolites in organisms, methods of producing plants having a terpene synthase activity of interest, having a terpene profile of interest or having a transporter activity of interest are disclosed. Methods of producing a terpene of interest are also disclosed.